JAGSNPHARM.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine...

Stats
Dagens volum	75 103.00
Gjennomsnittsvolum	46 729.00
Markedsverdi	9.27B
EPS	INR0 ( 2024-02-02 )
Neste inntjeningsdato	( INR0 ) 2024-05-20
Last Dividend	INR5.00 ( 2023-08-21 )
Next Dividend	INR0 ( N/A )
P/E	37.91
ATR14	INR0.483 (0.14%)

Volum Korrelasjon

Lang: -0.08 (neutral)

Kort: -0.50 (weak negative)

Signal:(69.751) Neutral

Jagsonpal Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
20MICRONS.NS	0.912
MUTHOOTFIN.NS	0.91
21STCENMGM.NS	0.902
DELPHIFX.NS	0.889
STAR.NS	0.887
ICICIPHARM.NS	0.887
KCP.NS	0.879
MEDICAMEQ.NS	0.877
IGPL.NS	0.876
PVP.NS	0.873

10 Mest negative korrelasjoner
RAJRILTD.NS	-0.926
4THDIM.NS	-0.912
LTGILTBEES.NS	-0.876
SYMPHONY.NS	-0.869
SRTRANSFIN.NS	-0.84
ISMTLTD.NS	-0.833
GNA.NS	-0.832
SHRIRAMEPC.NS	-0.807
JSL.NS	-0.801

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Jagsonpal Pharmaceuticals Korrelasjon - Valuta/Råvare

0.02
( neutral )

0.10
( neutral )

0.25
( neutral )

-0.10
( neutral )

0.58
( weak )

-0.03
( neutral )

Jagsonpal Pharmaceuticals Økonomi

Annual	2022
Omsetning:	INR2.37B
Bruttogevinst:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Omsetning:	INR2.37B
Bruttogevinst:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Omsetning:	INR2.26B
Bruttogevinst:	INR1.30B (57.49 %)
EPS:	INR7.48

FY	2021
Omsetning:	INR1.88B
Bruttogevinst:	INR1.07B (56.92 %)
EPS:	INR6.51

Financial Reports:

No articles found.

Jagsonpal Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Jagsonpal Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.51 - low (49.85%) | Divividend Growth Potential Score: 5.54 - Stable (10.77%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.75	2003-05-30
Last Dividend	INR5.00	2023-08-21
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR19.95	--
Avg. Dividend % Per Year	1.32%	--
Score	2.75	--
Div. Sustainability Score	4.51
Div.Growth Potential Score	5.54
Div. Directional Score	5.02	--

Next Divdend (Est)
(2024-07-05)

INR5.77 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.75

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.100	0.36%
2019	INR0.250	0.79%
2020	INR0.500	1.95%
2021	INR5.00	6.21%
2022	INR0	0.00%
2023	INR5.00	1.36%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SPAL.NS	Dividend Junior	2023-09-15	Sporadic	8	0.44%
MOTHERSON.NS	Dividend Junior	2023-08-11	Annually	23	0.63%
HERITGFOOD.NS	Dividend Junior	2023-08-14	Annually	23	0.44%
BIKAJI.NS	Dividend Junior	2023-06-08	Insufficient data to determine frequency	2	0.06%
RANEHOLDIN.NS	Dividend Junior	2023-07-27	Annually	21	0.95%
KOPRAN.NS	Dividend Junior	2023-09-07	Annually	5	1.18%
ESCORTS.NS	Dividend Junior	2023-06-30	Annually	28	0.21%
ALPHAGEO.NS	Dividend Junior	2023-09-22	Annually	18	2.07%
SYMPHONY.NS	Dividend Junior	2023-08-04	Semi-Annually	14	0.47%
NESCO.NS	Dividend Junior	2023-07-28	Annually	17	0.40%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.111	1.500	7.78	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	39.98	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.34	2.00	7.33	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.609	1.000	3.19	3.19	[0.2 - 0.8]
operatingProfitMarginTTM	0.144	1.000	9.13	9.13	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	37.70	1.000	6.29	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
dividendYielPercentageTTM	1.422	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	3.56	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0636	1.000	-0.909	0	[0.1 - 0.5]
Total Score				5.54

Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.